)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Sol-Gel Technologies
Sol-Gel Technologies (SLGL) investor relations material
Sol-Gel Technologies Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Achieved $19.4M in 2025 revenue, up from $11.6M in 2024, mainly from milestone and royalty payments related to licensing agreements for Twyneo and Epsolay.
Net loss narrowed to $6.1M in 2025 from $10.6M in 2024 and $27.2M in 2023; accumulated deficit reached $237M as of December 31, 2025.
Sold U.S. rights to Twyneo and Epsolay to Mayne Pharma for $16M; entered new licensing and commercialization agreements in Canada, China, and other territories.
SGT-610 (patidegib gel) Phase 3 trial for Gorlin syndrome completed enrollment; topline results expected Q4 2026.
SGT-610 granted Orphan Drug and Breakthrough Therapy designations by FDA; potential peak annual net sales estimated at $600M if approved.
Financial highlights
2025 revenue: $19.4M (2024: $11.6M; 2023: $1.6M).
2025 net loss: $6.1M (2024: $10.6M; 2023: $27.2M).
R&D expenses increased to $22.8M in 2025 (2024: $17.8M), mainly due to SGT-610 manufacturing and clinical trial costs.
Cash, cash equivalents, deposits, and marketable securities totaled $12.4M at year-end 2025; sufficient to fund operations into Q1 2027.
Accumulated deficit: $237M as of December 31, 2025.
Outlook and guidance
Topline results for SGT-610 Phase 3 trial in Gorlin syndrome expected in Q4 2026.
Evaluating SGT-610 for high-frequency BCC; feasibility study planned.
SGT-210 development to focus on small feasibility studies in new indications after discontinuing Darier disease program.
Company expects to incur significant expenses and operating losses for the foreseeable future and will require additional funding.
SGT-610 Phase 3 inclusion criteria rationale
Rationale for Mayne Pharma US rights deal
SGT-210 development plan after Darier failure
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sol-Gel Technologies
- SGT-610 aims to be the first preventive therapy for Gorlin syndrome, targeting a $600M+ market.SLGL
Corporate presentation16 Mar 2026 - Dermatology innovator seeks up to $120M via shelf registration after global licensing and share split.SLGLRegistration Filing16 Dec 2025
- Q3 2025 featured higher R&D costs, expanded licensing, and a net loss amid global growth plans.SLGLQ3 202520 Nov 2025
- Revenue surged to $11.5M in 2024 as net loss narrowed and key U.S. assets were monetized.SLGLQ4 202410 Sep 2025
- Q2 2025 revenue jumped to $17.2M and net income hit $11.6M, with cash runway into 2027.SLGLQ2 202519 Aug 2025
- Revenue up, net loss down, and pipeline plus licensing deals drive future growth.SLGLQ3 202413 Jun 2025
- Q2 revenue jumped to $5.4M with net income of $2.0M, extending cash runway into 2026.SLGLQ2 202413 Jun 2025
- Revenue up, losses widen as R&D accelerates; cash runway into 2027 amid industry risks.SLGLQ1 20256 Jun 2025
Next Sol-Gel Technologies earnings date
Q1 202614 May, 2026
Sol-Gel Technologies
Next Sol-Gel Technologies earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage